The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Initial Hep C Data on ACH-2928 Is Encouraging

Back to News Homepage

Next

Green Tea and Hepatitis C Post Liver Transplant

Biotron's BIT225 Shows Strong Hep C Antiviral Activity

December 12, 2011

Print this page

After three months, a Phase 2a trial of Biotron’s first-in-class direct acting Hepatitis C antiviral boasted a complete viral response for 87 percent of participants.

Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months

Wednesday, December 07, 2011 by Angela Kean

Biotron (ASX: BIT) has revealed positive results from a phase 2a trial of its lead Hepatitis C drug candidate, BIT225, that show 87% of patients receiving the drug had an undetectable virus after three months of treatment.

BIT225 targets the viral protein p7, which plays a crucial role in virus replication and reproduction. It is a new target, and BIT225 is a first-in-class direct acting antiviral.
The 28 day study treated patients with a combination of BIT225 and current approved standard of care therapies interferon alfa-2b plus ribavirin.

Continue reading this entire article:
http://www.proactiveinvestors.com.au/companies/news/23174/biotron-study-of-lead-hepatitis-c-drug-shows-virus-undetectable-in-patients-after-three-months–23174.html

No Comments - be the first!
Share
Share

Previous

Initial Hep C Data on ACH-2928 Is Encouraging

Back to News Homepage

Next

Green Tea and Hepatitis C Post Liver Transplant

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.